TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30975047

Group type: EXPERIMENTAL
Intervention: Telehealth care solution (Telekit)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 299
Study: 29427355

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Number of subjects: 97

Group type: COMPARATOR
Intervention: Observational arm
Number of subjects: 97
Study: 26536214

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no RIC)
Number of subjects: 0
Study: 24114969

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 μg once daily
Number of subjects: 528

Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol (FP/SAL) 500/50 μg twice daily
Number of subjects: 528
Study: 22422352

Group type: EXPERIMENTAL
Intervention: Oral administration (tablet)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Subcutaneous administration (injection)
Number of subjects: 178
Study: 19744283

Group type: EXPERIMENTAL
Intervention: ab initio calcineurin inhibitor-based monotherapy immunosuppression
Number of subjects: 203
Study: 17596275

Group type: EXPERIMENTAL
Intervention: Expert support group
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 16229636

Group type: EXPERIMENTAL
Intervention: Noninvasive glucose measurements using tissue modulated Raman spectroscopy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Fingerstick glucose measurements (HemoCue)
Number of subjects: 49
Study: 12117082

Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.1% ophthalmic solution
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.2% ophthalmic suspension
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 10195537

Group type: EXPERIMENTAL
Intervention: 40 mL of mepivacaine 1% with 100 mg of tramadol (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 40 mL of mepivacaine 1% (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 40 mL of mepivacaine 1% with 2 mL of isotonic sodium chloride solution and 100 mg of tramadol i.v. (Group C)
Number of subjects: 60
Study: 7782256

Group type: EXPERIMENTAL
Intervention: Mupirocin calcium ointment, intranasally bid for 5 days
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Mupirocin calcium ointment
Number of subjects: 68
Study: 2331280

Group type: EXPERIMENTAL
Intervention: Education and self‐palpation (EP)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Education and an ambulatory monitor (EM)
Number of subjects: 76
Study: 7416559

Group type: EXPERIMENTAL
Intervention: Sublingual food drops (egg, corn, milk, yeast)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31994511

Group type: EXPERIMENTAL
Intervention: Lurasidone (40, 80, 120 or 160 mg/d)
Number of subjects: 230
Study: 29233028

Group type: EXPERIMENTAL
Intervention: 50 µg liothyronine via nasogastric tube after gastric lavage, in the first 6 h of poisoning
Number of subjects: 24

Group type: COMPARATOR
Intervention: Routine treatment of AlP poisoning (control group)
Number of subjects: 24
Study: 26110350

Group type: EXPERIMENTAL
Intervention: Eccentric overload training (6-week squat training in the flywheel)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untrained group (control)
Number of subjects: 20
Study: 24060707

Group type: EXPERIMENTAL
Intervention: Pamidronate 30 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pamidronate 180 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 22610936

Group type: EXPERIMENTAL
Intervention: Goal-setting and Planning (GAP)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 55
Study: 19282040

Group type: EXPERIMENTAL
Intervention: Hydrotherapy (HT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional gyms (no-hydrotherapy group=NHTG)
Number of subjects: 70
Study: 17868675

Group type: EXPERIMENTAL
Intervention: Surgical closure of obstetric fistulas (vaginal, abdominal, and combined approaches)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged bladder drainage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formal operative repair of mature fistulas
Number of subjects: 0
Study: 16032582

Group type: EXPERIMENTAL
Intervention: Radial-nerve stimulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Median-nerve stimulation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Radial-nerve plus musculocutaneous-nerve stimulation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Triple-nerve stimulation
Number of subjects: 120
Study: 12383144

Group type: EXPERIMENTAL
Intervention: Medication improvement program (usual care with intervention)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 259
Study: 10619540

Group type: EXPERIMENTAL
Intervention: Relaxation training (six sessions before exposure)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No relaxation training (control group)
Number of subjects: 20
Study: 8909433

Group type: EXPERIMENTAL
Intervention: BCAA (L-leucine 12 g, L-isoleucine 8 g, L-valine 6.4 g daily)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: L-threonine (4 g daily) with pyridoxal phosphate (160 mg daily)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: BCAA and L-threonine
Number of subjects: 95

Group type: COMPARATOR
Intervention: BCAA, L-threonine, and placebo
Number of subjects: 95
Study: 1749780

Group type: EXPERIMENTAL
Intervention: Freshly mixed glass ionomer (Ketac‐Fil)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Artificially aged glass ionomer (Ketac‐Fil)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Freshly mixed silver glass ionomer (Ketac‐Silver)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Light‐cured hybrid composite (Valux)
Number of subjects: 10
Study: 6749576

Group type: EXPERIMENTAL
Intervention: Nabumetone (1000 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Naproxen (500 mg/day)
Number of subjects: 30
Study: 31070770

Group type: EXPERIMENTAL
Intervention: Sentinel node navigation surgery (SNNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systematic lymphadenectomy
Number of subjects: 0
Study: 29402701

Group type: EXPERIMENTAL
Intervention: Early and systematic integration of palliative care
Number of subjects: 186

Group type: COMPARATOR
Intervention: Standard oncological care
Number of subjects: 186
Study: 26918662

Group type: EXPERIMENTAL
Intervention: BNX-RDT
Number of subjects: 566

Group type: COMPARATOR
Intervention: BNX film
Number of subjects: 566
Study: 23958793

Group type: EXPERIMENTAL
Intervention: Resveratrol (150mg per day for 30 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 22673600

Group type: EXPERIMENTAL
Intervention: Sarpogrelate
Number of subjects: 127

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 127
Study: 20456285

Group type: EXPERIMENTAL
Intervention: Multifaceted educational intervention (1 day of didactic lectures, six 3-hour educational outreach visits, and an electronic reminder during drug prescribing)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 232
Study: 17508623

Group type: EXPERIMENTAL
Intervention: Automated Flossing Device (AF)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Manual Flossing (M)
Number of subjects: 76
Study: 16213238

Group type: EXPERIMENTAL
Intervention: Feedback group walking on a treadmill for 15 minutes, 3 times a week for 8 weeks while matching step-to-step reaction forces.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: No-feedback group walking for equal time without feedback.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group did not train.
Number of subjects: 28
Study: 11834122

Group type: EXPERIMENTAL
Intervention: Access bar and water
Number of subjects: 12

Group type: COMPARATOR
Intervention: Uncle Tobys Peanut Butter Muesli Bar and water
Number of subjects: 12

Group type: COMPARATOR
Intervention: Crystal Light
Number of subjects: 12
Study: 10075382

Group type: EXPERIMENTAL
Intervention: High sodium diet
Number of subjects: 70

Group type: COMPARATOR
Intervention: Low sodium diet
Number of subjects: 70
Study: 7733042

Group type: EXPERIMENTAL
Intervention: Sugar fortified with 1 g FeNaEDTA and 15 mg retinol as retinyl palmitate/kg
Number of subjects: 17000

Group type: COMPARATOR
Intervention: Vitamin A‐fortified sugar (control)
Number of subjects: 17000
Study: 2139303

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 0
Study: 7164001

Group type: EXPERIMENTAL
Intervention: Naloxone (0.1 mg/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 19
Study: 31204836

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: CBT integrated with motivational interviewing
Number of subjects: 85
Study: 30726693

Group type: COMPARATOR
Intervention: Givosiran (0.35 or 1.0 mg/kg) once-monthly injections in part B
Number of subjects: 40

Group type: COMPARATOR
Intervention: Givosiran (2.5 or 5.0 mg/kg) once-monthly injections in part C
Number of subjects: 40

Group type: COMPARATOR
Intervention: Givosiran (0.035, 0.10, 0.35, 1.0, or 2.5 mg/kg) single subcutaneous injection in part A
Number of subjects: 40

Group type: COMPARATOR
Intervention: Givosiran (once-monthly or once-quarterly injections in part C)
Number of subjects: 40
Study: 27919300

Group type: EXPERIMENTAL
Intervention: Transcranial pulsed electromagnetic fields (PEMF) for 6 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo PEMF (no stimulation) for 6 weeks
Number of subjects: 39
Study: 26823793

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cyclophosphamide (500 mg/m2 pemetrexed + 20 mg/kg cyclophosphamide)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Pemetrexed monotherapy (500 mg/m2 pemetrexed)
Number of subjects: 62
Study: 25549103

Group type: EXPERIMENTAL
Intervention: 40 mg of propranolol HCl administered orally after memory reactivation phase.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 0
Study: 22884505

Group type: COMPARATOR
Intervention: Intravenous trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance dose)
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (fixed dose of 600 mg)
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 596
Study: 19482490

Group type: EXPERIMENTAL
Intervention: Computer-assisted glenoid implantation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Traditional glenoid implantation
Number of subjects: 16
Study: 17623343

Group type: EXPERIMENTAL
Intervention: Treatment (T)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0
Study: 17334935

Group type: EXPERIMENTAL
Intervention: Routine upstream tirofiban
Number of subjects: 548

Group type: COMPARATOR
Intervention: Selective down stream tirofiban
Number of subjects: 548
Study: 15233825

Group type: EXPERIMENTAL
Intervention: Immunosuppression started 3 days before transplantation (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Immunosuppression started on the first day after surgery (n = 30)
Number of subjects: 60
Study: 10601401

Group type: EXPERIMENTAL
Intervention: Stroke family care worker intervention
Number of subjects: 372
Study: 9187434

Group type: EXPERIMENTAL
Intervention: CHVmP-VB (cyclophosphamide, hydroxorubicin, Vm-26, prednisone + vincristine and bleomycin)
Number of subjects: 140

Group type: COMPARATOR
Intervention: CHVmP (cyclophosphamide, hydroxorubicin, Vm-26, prednisone)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: CHVmP-VB
Number of subjects: 140

Group type: COMPARATOR
Intervention: CHVmP
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: CHVmP-VB and CHVmP
Number of subjects: 140
Study: 1336998

Group type: EXPERIMENTAL
Intervention: Low dose arginine-vasopressin (AVP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher doses of arginine-vasopressin (AVP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 4007463

Group type: EXPERIMENTAL
Intervention: Suprapubic catheterisation (SC)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Transurethral catheterisation (TC)
Number of subjects: 157
Study: 29140227

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 3384

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 3384

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3384
Study: 27582239

Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no SMS reminders)
Number of subjects: 200
Study: 25660493

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg twice daily)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 23599642

Group type: EXPERIMENTAL
Intervention: BB536-H (5 × 10¹⁰ cfu)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: BB536-L (2.5 × 10¹⁰ cfu)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: BB536-L and BB536-H
Number of subjects: 206
Study: 21570111

Group type: EXPERIMENTAL
Intervention: Oxaliplatin and fluorouracil (group B)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Capecitabine (group C)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Oxaliplatin (group B)
Number of subjects: 459
Study: 19324253

Group type: EXPERIMENTAL
Intervention: Adjunctive cilostazol (triple group; n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High maintenance dose clopidogrel (high-MD group; n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adjunctive cilostazol (triple group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High maintenance dose clopidogrel (high-MD group)
Number of subjects: 60
Study: 16964595

Group type: EXPERIMENTAL
Intervention: HB‐AS04 vaccine (2 doses)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Licensed HB vaccine (3 double doses)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: HB‐AS04 vaccine (in subjects who did not undergo liver transplantation before booster)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Licensed HB vaccine (in subjects who did not undergo liver transplantation before booster)
Number of subjects: 93
Study: 15476476

Group type: EXPERIMENTAL
Intervention: Sirolimus/MMF/P
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cyclosporine/MMF/P
Number of subjects: 61
Study: 11794893

Group type: EXPERIMENTAL
Intervention: Short anticoagulant course (3 months) for patients with temporary risk factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer anticoagulant course (6 months at least) for cases with permanent risk factors or idiopathic venous thromboembolism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-week treatment for isolated calf vein thrombosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long course of oral anticoagulant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low- or fixed-dose oral anticoagulation
Number of subjects: 0
Study: 9862108

Group type: EXPERIMENTAL
Intervention: Collagen dressing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Polyurethane dressing
Number of subjects: 20
Study: 7832080

Group type: EXPERIMENTAL
Intervention: Sairei-to
Number of subjects: 167
Study: 3060191

Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.15 mg kg‐1, intramuscular)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Haloperidol (oral, twice daily for 2 days)
Number of subjects: 12
Study: 31034303

Group type: EXPERIMENTAL
Intervention: Virtual kayak paddling (VKP) exercise for 60 min twice a week for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group performing home exercises
Number of subjects: 60
Study: 28237861

Group type: EXPERIMENTAL
Intervention: PF‐06291874 15mg once daily for 28 days
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: PF‐06291874 35mg once daily for 28 days
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: PF‐06291874 75mg once daily for 28 days
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: PF‐06291874 150mg once daily for 28 days
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: PF‐06291874
Number of subjects: 172
Study: 25782738

Group type: EXPERIMENTAL
Intervention: Re-irradiation for painful bone metastases
Number of subjects: 119
Study: 24022532

Group type: EXPERIMENTAL
Intervention: Preoperative oral antibiotics (500 mg of kanamycin and 500 mg of metronidazole) plus intravenous antimicrobial prophylaxis
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intravenous antimicrobial prophylaxis alone
Number of subjects: 200
Study: 21500960

Group type: EXPERIMENTAL
Intervention: Training to visually fixate a video image in response to an internal cue (opening own mouth)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Training to visually fixate a video image in response to an external cue (seeing a face open its mouth)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Training to visually fixate a video image in response to both internal and external cues
Number of subjects: 173
Study: 18344842

Group type: COMPARATOR
Intervention: Short-term MV (n = 40)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Long-term MV (n = 10)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Unilateral VAP (n = 4)
Number of subjects: 54
Study: 17067370

Group type: EXPERIMENTAL
Intervention: Motor imagery training (daily mental rehearsal of movements with affected arm for 4 weeks)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Non-motor mental rehearsal (closely supervised)
Number of subjects: 135

Group type: COMPARATOR
Intervention: No training program (control group)
Number of subjects: 135
Study: 15603467

Group type: EXPERIMENTAL
Intervention: Dynamic display AAC technologies in a contextual scene format
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dynamic display AAC technologies in a grid format
Number of subjects: 10
Study: 10617781

Group type: EXPERIMENTAL
Intervention: Phonological recoding
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Orthographic lexical representations
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Implicit phonological recoding process
Number of subjects: 1
Study: 9106560

Group type: EXPERIMENTAL
Intervention: Inhaled magnesium sulfate (4 mL; 286 mOsm)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 10
Study: 8245054

Group type: EXPERIMENTAL
Intervention: Total hip replacement with cement
Number of subjects: 188

Group type: COMPARATOR
Intervention: Total hip replacement without cement
Number of subjects: 188
Study: 3545476

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control (tobramycin plus ticarcillin)
Number of subjects: 94
Study: 28602935

Group type: EXPERIMENTAL
Intervention: Standard KT tension (n = 26)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Increased KT tension (n = 25)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No KT tension (n = 24)
Number of subjects: 75
Study: 27229354

Group type: EXPERIMENTAL
Intervention: Patellar tendon (PT) autograft
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Hamstring tendon (HT) autograft
Number of subjects: 193

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 193
Study: 24720885

Group type: EXPERIMENTAL
Intervention: GDM group (n = 16)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Lean group (n = 15)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Obese group without GDM (n = 13)
Number of subjects: 44
Study: 23602798

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaBic) 60 mEq/day for 3 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Potassium citrate (KCit) 60 mEq/day for 3 days
Number of subjects: 16
Study: 20625021

Group type: EXPERIMENTAL
Intervention: Severely serum 25(OH)D deficient (levels <25 nmol/L)
Number of subjects: 858

Group type: COMPARATOR
Intervention: Sufficient levels of 25(OH)D (>/=75 nmol/L)
Number of subjects: 858
Study: 21197285

Group type: EXPERIMENTAL
Intervention: Preemptive lumiracoxib 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative lumiracoxib 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16603063

Group type: EXPERIMENTAL
Intervention: Intravenous and oral prednisolone
Number of subjects: 210
Study: 14740601

Group type: EXPERIMENTAL
Intervention: Intravenous verapamil (0.1 mg/kg)
Number of subjects: 0
Study: 11310385

Group type: COMPARATOR
Intervention: Unrestricted diet (Group I, 20 patients)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Protein restricted diet (Group II, 25 patients, 0.6 g/kg/day, 50% high biological value)
Number of subjects: 45
Study: 9307742

Group type: EXPERIMENTAL
Intervention: Tiludronate 200 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiludronate 400 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiludronate 600 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiludronate (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiludronate
Number of subjects: 0
Study: 8346591

Group type: EXPERIMENTAL
Intervention: Maxon 4-0 sutures
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vicryl 3-0 sutures
Number of subjects: 50
Study: 3520902

Group type: EXPERIMENTAL
Intervention: gentamicin and metronidazole
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: moxalactam
Number of subjects: 86
Study: 29114972

Group type: EXPERIMENTAL
Intervention: ATRA and double induction intensified by high-dose cytosine arabinoside (HD ara‐C)
Number of subjects: 80

Group type: COMPARATOR
Intervention: ATRA and anthracyclines
Number of subjects: 80
Study: 26884390

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24713426

Group type: EXPERIMENTAL
Intervention: SAFE Children intervention (n = 232)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: SAFE Children booster intervention (n = 101)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Control condition (n = 192)
Number of subjects: 424